by EmpathiCSubstanceS | Aug 17, 2022 | Psilocybin Magic Mushroom, Psychedelic Research
All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month...
by EmpathiCSubstanceS | Aug 17, 2022 | Psilocybin Magic Mushroom, Psychedelic Research
Outcomes at 6 months included rates of spiritual practice and persisting effects of psilocybin. Compared with low-dose, high-dose psilocybin produced greater acute and persisting effects. At 6 months, compared with LD-SS, both high-dose groups showed large significant...
by EmpathiCSubstanceS | Aug 17, 2022 | Psilocybin Magic Mushroom, Psychedelic Research
Abstainers scored significantly higher on a measure of psilocybin-occasioned mystical experience. No significant differences in general intensity of drug effects were found between groups, suggesting that mystical-type subjective effects, rather than overall intensity...
by EmpathiCSubstanceS | Aug 17, 2022 | Psilocybin Magic Mushroom
The present pilot study demonstrated that up to 2 mg of psilocybin delivered as a slow intravenous injection produces short-lived but typical drug effects that are psychologically and physiologically well tolerated. With appropriate care, this study supports the...
by EmpathiCSubstanceS | Aug 17, 2022 | Psilocybin Magic Mushroom, Psychedelic Research
Robust activations to the memories were seen in limbic and striatal regions in the early phase and the medial prefrontal cortex in the late phase in both conditions (P<0.001, whole brain cluster correction), but there were additional visual and other sensory...
by EmpathiCSubstanceS | Aug 12, 2022 | Bipolar Disorder, Chronic Pain, Kambo, LSD, MDMA Sassafras Molly, Microdosing, NN-Dimethyltryptamine, OCD, Psilocybin Magic Mushroom, Psychedelic Medicine
COULD AN OVERACTIVE IMMUNE SYSTEM make you depressed? In the late 1990s, psychiatrist Andrew Miller and his colleagues began to notice that patients with cancer, cardiovascular disease, obesity and Crohn’s disease—all conditions that cause higher than normal levels of...
